Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials

BackgroundWe sought to examine the efficacy and safety of 2 PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors: alirocumab and evolocumab. Methods and ResultsWe performed a systematic review and meta‐analysis of randomized controlled trials comparing treatment with and without PCSK9 in...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Aris Karatasakis, Barbara A Danek, Judit Karacsonyi, Bavana V Rangan, Michele K Roesle, Thomas Knickelbine, Michael D Miedema, Houman Khalili, Zahid Ahmad, Shuaib Abdullah, Subhash Banerjee, Emmanouil S. Brilakis
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Wiley 2017-12-01
Цуврал:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Нөхцлүүд:	alirocumab evolocumab hyperlipidemia outcome PCSK9
Онлайн хандалт:	https://www.ahajournals.org/doi/10.1161/JAHA.117.006910
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!